陇神戎发(300534) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 289,443,116.82, representing a 13.52% increase compared to CNY 254,914,282.74 in the same period last year[5]. - Net profit attributable to shareholders was CNY 24,210,004.50, up 9.18% from CNY 22,141,028.38 year-on-year[5]. - The net profit after deducting non-recurring gains and losses increased by 26.88% to CNY 26,922,986.49 from CNY 21,218,616.75 in the previous year[5]. - Total operating revenue for the current period reached ¥289,443,116.82, an increase of 13.5% compared to ¥254,961,825.33 in the previous period[23]. - Net profit for the current period was ¥32,876,395.14, representing a growth of 6.6% from ¥30,849,905.40 in the previous period[24]. - The company's gross profit margin improved to approximately 16.5%, compared to 14.5% in the previous period[23]. - Basic earnings per share rose to ¥0.0798 from ¥0.0731, an increase of 9.2%[25]. Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 124.47% to -CNY 32,384,718.82, compared to CNY 84,710,636.25 in the same period last year[5]. - Operating cash inflow totaled $326,936,319.75, down from$342,028,825.91 in the previous period, representing a decrease of approximately 4.1%[27]. - Operating cash outflow increased significantly to $359,321,038.57 from$209,706,087.53, marking an increase of about 71.4%[28]. - Cash received from sales of goods and services was $312,167,100.41, down from$325,603,955.80, reflecting a decrease of about 4.1%[27]. - Payments for goods and services increased significantly to $109,909,800.69 from$50,171,363.98, an increase of approximately 118.5%[27]. - Payments to employees rose to $27,773,229.79 from$23,837,921.36, an increase of about 16.5%[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,433,541,057.65, a decrease of 0.91% from CNY 1,402,312,065.83 at the end of the previous year[5]. - The total assets decreased slightly to ¥1,433,541,057.65 from ¥1,446,715,474.87, a decline of 0.9%[21]. - Total liabilities decreased to ¥666,647,200.24 from ¥706,898,011.15, a reduction of 5.7%[21]. - The company's equity increased to ¥766,893,857.41, up from ¥739,817,463.72, reflecting a growth of 3.7%[21]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,777, with the largest shareholder holding 29.93% of the shares[11]. - The company reported a total of 90,785,250 shares held by Gansu Pharmaceutical Investment Group Co., Ltd., representing 0.55% of total shares[12]. - The top ten shareholders include Gansu Xinglong Capital Management Co., Ltd. with 21,575,777 shares, accounting for 0.47% of total shares[12]. - The total number of shares held by the top ten unrestricted shareholders is 90,785,250, with no changes reported in the financing and securities lending activities[12]. - The company has not disclosed any significant changes in the shareholder relationships or actions among the top ten shareholders[12]. Research and Development - Research and development expenses increased to ¥5,999,802.11, up from ¥5,178,710.13, indicating a focus on innovation[23]. - The company acquired 70% equity of Gansu Pharmaceutical Group Technology Innovation Research Institute for RMB 85.8494 million to enhance its research capabilities and market competitiveness[16]. - The company has completed the industrial and commercial registration for the acquisition of the research institute, which is now included in the consolidated financial statements[16]. - The company aims to reduce related party transactions and enhance its independence through this acquisition[16]. Operating Costs and Expenses - The company's operating costs increased by 58.03% year-on-year, primarily due to increased sales revenue from pharmaceuticals and lower gross margins from medical devices[9]. - Total operating costs amounted to ¥247,299,967.41, up from ¥221,232,697.25, reflecting a rise of 11.8%[23]. - The company reported a significant increase in sales expenses, totaling ¥118,896,805.76, compared to ¥135,189,244.13 in the previous period, indicating a strategic shift in marketing efforts[23]. - The company reported a 75.00% decrease in financial expenses compared to the previous year, attributed to loan repayments and increased interest income[9]. Cash and Cash Equivalents - As of March 31, 2025, the company's cash and cash equivalents decreased to RMB 274,849,268.71 from RMB 310,022,521.29 at the beginning of the period, reflecting a decline of approximately 11.4%[19]. - The ending cash and cash equivalents balance decreased to $274,849,268.71 from$340,758,258.95, a decline of approximately 19.3%[28].